Raymond James Financial
GSK icon

Raymond James Financial’s GSK GSK Stock Holding History

Raymond James Financial’s Portfolio GSK Stock Details GSK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-22,900
Closed -$824K – 4865
2024
Q4 		$824K Buy
+22,900
New +$824K ﹤0.01% 3578

Other funds holding GSK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
JEST
JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Raymond James Financial's GSK Position: Q1 2026 in Review

Raymond James Financial reduced its GSK (GSK) stake by 45% in Q1 2026, selling an estimated $59.8M and leaving 1,371,577 shares worth $75.7M. The position accounts for 0.02% of the portfolio, ranked #630.

Raymond James Financial first reported a position in GSK in Q4 2024 and has held it in 6 quarters since. The position peaked at $121M in Q4 2025. 1,031 funds tracked by Wall St. Rank hold GSK as of Q1 2026.

  • Raymond James Financial held 1,371,577 shares of GSK worth $75.7M as of Q1 2026.
  • Raymond James Financial sold 1,104,162 GSK shares in Q1 2026, an estimated $59.8M.
  • GSK made up 0.02% of Raymond James Financial's portfolio in Q1 2026, its #630 holding.
  • Raymond James Financial first reported a position in GSK in Q4 2024 and has held it in 6 quarters since.
  • Raymond James Financial's GSK position peaked at $121M in Q4 2025.
  • 1,031 funds tracked by Wall St. Rank held GSK as of Q1 2026.

Based on Raymond James Financial's 13F filing for Q1 2026, filed 14 May 2026.